^
    Back
    Association details:
    Biomarker:KIT V654A
    Cancer:Gastrointestinal Stromal Tumor
    Drug:Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.

    Published date:
    05/26/2022
    Excerpt:
    mTTF for KIT exon 13 V654 pts treated with 2L+ sunitinib, imatinib 800mg, or other was 10.8, 7.5, and 3.7 months, respectively. TTF for sunitinib vs other 2L+ drugs showed a HR of 0.51 (CI 0.33-0.8), p = 0.003….GIST pts with KIT exon 13 V654 resistance mutations had superior outcomes in the 2L+ setting with sunitinib.
    DOI:
    10.1200/JCO.2022.40.16_suppl.11514